Advanced Science-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2024-04-20 ms1000000197918585 来自江苏省

偏重的研究方向：医学
经验分享：投了三个月，under review了快三个月，不知道还要等多久

2 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2024-04-20 ms1000000197918585 来自江苏省

偏重的研究方向：医学
经验分享：Under Review都快三个月了，这正常吗？

2 0

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2024-04-20 leileiliu 来自陕西省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫治疗
经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。
11.11 Submitted manuscript to AM
11.17 With editor
11.21 Edited recommend transfer to Advanced Science
11.24 Submitted manuscript to AS
12.05 With editor
12.05 Under Review
12.23 Required Reviews Completed
12.24 Major Revision
02.14 Revised Manuscript Submitted
02.19 Under Review
03.05 Required Reviews Completed
03.07 Reject
03.19 Appeal with editor
03.27 Supplement Appeal Material
04.11 Editor Suggested to Re-Submit
04.12 Re-Submitted to AS
04.17 With editor
04.19 Accept without change

2 0

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2023-08-12 124a8810m95(暂无昵称) 来自重庆

这个期刊和大CDD比起来怎么样啊？

95 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2022-12-14 ms6000000798925478 来自广东省

12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞

67 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2023-10-19 ms10085448 来自江苏省

大修送回去，要审多久才有消息啊？听说有的要两三个月……

65 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2023-12-28 ms1000000907051820 来自河南省

偏重的研究方向：医学;医学基础
经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪

73 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2024-04-04 123cda67m26(暂无昵称) 来自上海

怎么这么慢，with editory已经9天了

9 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2024-04-13 ms9000000188651574 来自吉林省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：生物医学;代谢;疾病
经验分享：2024.03.06 Manuscript Submitted
2024.03.12 With Editor
2024.03.12 Under Review
2024.04.11 Reject
提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。

6 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2199501, encodeId=993e2199501d6, content=偏重的研究方向：医学 经验分享：投了三个月，under review了快三个月，不知道还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:11:40 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199499, encodeId=686c219949970, content=偏重的研究方向：医学 经验分享：Under Review都快三个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0e9138354, createdName=ms1000000197918585, createdTime=Sat Apr 20 22:03:59 CST 2024, time=2024-04-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2199426, encodeId=cf322199426fb, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：经历了transfer，修回被拒，申诉，终于还是接收了。其实前期一直算是比较顺利，但是二审后突然收到拒搞邮件，理由是动物伦理问题，但是我们实验过程中确实不存在伦理问题，经过两轮的申诉最终成功的驳回了拒搞决定，编辑让重投，很快就接收了。给大家贡献一波时间线。 11.11 Submitted manuscript to AM 11.17 With editor 11.21 Edited recommend transfer to Advanced Science 11.24 Submitted manuscript to AS 12.05 With editor 12.05 Under Review 12.23 Required Reviews Completed 12.24 Major Revision 02.14 Revised Manuscript Submitted 02.19 Under Review 03.05 Required Reviews Completed 03.07 Reject 03.19 Appeal with editor 03.27 Supplement Appeal Material 04.11 Editor Suggested to Re-Submit 04.12 Re-Submitted to AS 04.17 With editor 04.19 Accept without change, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9872044598, createdName=leileiliu, createdTime=Sat Apr 20 10:02:39 CST 2024, time=2024-04-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163811, encodeId=e896216381150, content=大修送回去，要审多久才有消息啊？听说有的要两三个月……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae298747425, createdName=ms10085448, createdTime=Thu Oct 19 20:58:36 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2196930, encodeId=4ba6219693084, content=怎么这么慢，with editory已经9天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93862438625, createdName=123cda67m26(暂无昵称), createdTime=Thu Apr 04 17:33:38 CST 2024, time=2024-04-04, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198343, encodeId=06bb219834338, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：生物医学;代谢;疾病 经验分享：2024.03.06 Manuscript Submitted 2024.03.12 With Editor 2024.03.12 Under Review 2024.04.11 Reject 提交之后很快送审，两个审稿人，审稿人1不认可工作内容。文章在讨论中明确提出有类似工作已经发表，但仍未改变审稿人的固有印象，其意见也十分不专业，并且严重缺乏本研究的相关背景知识，并未提出实质性修改意见但建议reject。审稿人2总共提供了7点意见，其中有两个实验上的补充验证。总的来说体验不算很好，但是审稿速度相对较快，上升类期刊，有生物医学相关稿件可以一试。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba519116540, createdName=ms9000000188651574, createdTime=Sat Apr 13 23:57:05 CST 2024, time=2024-04-13, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2159687, encodeId=b973215968e1a, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学工程 经验分享：3.15submit 3.21under review 4.10返修 4.28再投递 6.6拒稿 23.6.27 申诉后重新submit 23.8.7返回 23.8.24 resubmit 23.9.23 接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23f48383052, createdName=ms3000001364437971, createdTime=Mon Sep 25 23:33:16 CST 2023, time=2023-09-25, status=1, ipAttribution=北京)]

2023-09-25 ms3000001364437971 来自北京

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：医学工程
经验分享：3.15submit
3.21under review
4.10返修
4.28再投递
6.6拒稿
23.6.27 申诉后重新submit
23.8.7返回
23.8.24 resubmit
23.9.23 接收

62 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务